



Fragility fractures in Europe: burden, management and opportunities

Fredrik Borgström^{1,2} · Linda Karlsson² · Gustav Ortsäter² · Nicolas Norton² · Philippe Halbout³ · Cyrus Cooper^{4,5} · Mattias Lorentzon^{6,7} · Eugene V. McCloskey^{8,9} · Nicholas C. Harvey⁴ · Muhamamd K. Javaid⁵ · John A. Kanis^{6,8} ·
for the International Osteoporosis Foundation

Received: 6 December 2019 / Accepted: 28 January 2020
© The Author(s) 2020

Abstract

Summary This report provides an overview and a comparison of the burden and management of fragility fractures in the largest five countries of the European Union plus Sweden (EU6). In 2017, new fragility fractures in the EU6 are estimated at 2.7 million with an associated annual cost of €37.5 billion and a loss of 1.0 million quality-adjusted life years.

Introduction Osteoporosis is characterized by reduced bone mass and strength, which increases the risk of fragility fractures, which in turn, represent the main consequence of the disease. This report provides an overview and a comparison of the burden and management of fragility fractures in the largest five EU countries and Sweden (designated the EU6).

Methods A series of metrics describing the burden and management of fragility fractures were defined by a scientific steering committee. A working group performed the data collection and analysis. Data were collected from current literature, available retrospective data and public sources. Different methods were applied (e.g. standard statistics and health economic modelling), where appropriate, to perform the analysis for each metric.

Results Total fragility fractures in the EU6 are estimated to increase from 2.7 million in 2017 to 3.3 million in 2030; a 23% increase. The resulting annual fracture-related costs (€37.5 billion in 2017) are expected to increase by 27%. An estimated 1.0 million quality-adjusted life years (QALYs) were lost in 2017 due to fragility fractures. The current disability-adjusted life years (DALYs) per 1000 individuals age 50 years or more were estimated at 21 years, which is higher than the estimates for stroke or chronic obstructive pulmonary disease. The treatment gap (percentage of eligible individuals not receiving treatment with osteoporosis drugs) in the EU6 is estimated to be 73% for women and 63% for men; an increase of 17% since 2010. If all patients who fracture in the EU6 were enrolled into fracture liaison services, at least 19,000 fractures every year might be avoided.

Conclusions Fracture-related burden is expected to increase over the coming decades. Given the substantial treatment gap and proven cost-effectiveness of fracture prevention schemes such as fracture liaison services, urgent action is needed to ensure that all individuals at high risk of fragility fracture are appropriately assessed and treated.

Keywords Disability-adjusted life years · Fragility fracture · Fracture costs · Treatment gap · Quality-adjusted life years

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s11657-020-0706-y>) contains supplementary material, which is available to authorized users.

✉ John A. Kanis
w.j.Pontefract@shef.ac.uk

¹ Medical Management Centre, Department of Learning Informatics, Management and Ethics, Karolinska Institute, Solna, Sweden

² Quantify Research, Stockholm, Sweden

³ International Osteoporosis Foundation, Nyon, Switzerland

⁴ MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

⁵ National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK

⁶ Mary MacKillop Health Institute, Catholic University of Australia, Melbourne, Australia

⁷ Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁸ Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK

⁹ MRC and Arthritis Research UK Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK

Introduction

The objective of this report is to provide information on the current and future burden of osteoporosis and associated fragility fractures as well as to describe current management of the disease. Results are presented for the five largest EU countries (France, Germany, Italy, Spain and the UK) as well as Sweden, referred to as the EU6. This report was developed by the International Osteoporosis Foundation (IOF) and led by a steering committee of scientific experts assigned by the IOF. The report forms the basis of policy reports prepared by IOF for each of the EU6 countries [1–7].

To facilitate an assessment and a comparison of the burden and management of fragility fractures, a series of metrics was defined by a steering committee and thereafter quantified by a group of analysts at Quantify Research (reflected in the authorship). The metrics were classified into two broad categories with subcategories. The first category was burden of disease with epidemiology, economic cost and patient burden as subcategories. The second category was management of disease with service provision and service uptake as subcategories. The first part of this report provides a summary of the most important findings. An appendix that follows provides more detailed information on each metric, particularly on the analytic methods.

Osteoporosis

Osteoporosis, which means porous bone, is a disease that weakens the bones and increases the risk of fragility fractures, where bones can break from low level impact or stress that would not normally break a healthy bone. Since bones become more porous and fragile with age, the disease is mainly found in the older population, and is more common among women than men [8].

Bone mineral density (BMD) is the measurement used to determine whether an individual has osteoporosis. The operational definition of osteoporosis is based on the T-score for BMD in women [9, 10] and is defined as a value for BMD 2.5 SD or more below the young female adult mean (T-score less than or equal to -2.5).

The clinical relevance of osteoporosis lies in the associated fragility fractures; until such an event occurs, there are usually no symptoms [8]. In the Western World, about 1 in 3 women and 1 in 5 men

above 50 years of age will fracture during their remaining life time [11]. After the age of 50 years, most sites of fracture can be considered characteristic of osteoporosis. Fractures at the hip and vertebrae are among the most common and serious sites of osteoporotic fracture. Fragility fractures of the humerus, forearm, ribs, tibia (in women, but not including ankle fractures), pelvis and other femoral fractures after the age of 50 years are fractures associated with low BMD [12, 13].

Worldwide, osteoporosis causes more than 9 million fractures a year, meaning there is a fragility fracture every 3 s [14]. Those who have had their first osteoporotic fracture have a higher risk for further fractures. The risk of fracture also increases with age, and as average life expectancy around the world rises, more individuals are expected to sustain fragility fractures.

The fracture-related monetary cost of fragility fractures in the 27 countries of the EU (EU27) has been estimated at €37 billion in 2010 [15], with 26,300 life years lost and 1.16 million quality-adjusted life years (QALYs) lost on a yearly basis [15]. With changing demography, these costs are expected to increase considerably by the year 2030.

Despite significant impacts on health and quality of life for the older population, there is a general lack of awareness of osteoporosis, including many health care agencies, which results in suboptimal care. Indeed, most individuals at high risk are never identified nor given appropriate treatment, which gives rise to further fragility fractures and worsening of health status.

The primary outcomes of interest in this report were fractures considered to be related to low BMD [12]. These include clinical vertebral fractures, fractures of distal forearm, pelvis-sacrum, ribs-sternum, clavicle, humerus and proximal femur. Fractures of the hands, feet, ankle, skull and facial bones were excluded. The report also focuses on specific fracture sites: hip fracture, clinical vertebral fracture and major osteoporotic fracture (MOFs). MOF is a grouping of the most common fractures comprising hip, clinical vertebral, distal forearm and proximal humerus fractures. The term ‘other’ osteoporotic fractures in this report refers to osteoporotic fractures that are not MOFs unless specifically defined. The majority of vertebral fractures are subclinical (75%) and recognised on radiographs by a change in shape of the vertebral body [10]. In the present report, clinical vertebral fractures coming to medical attention are considered rather than these morphometric fractures.




Fig. 1 Prevalence of osteoporosis in the EU6 by age and sex

Epidemiology of fragility fractures

Prevalence of osteoporosis

About one-tenth of women age 60 years, one-fifth of women age 70, two-fifths of women age 80 and two-thirds of women aged 90 years have osteoporosis and an increased risk of fragility fracture [16]. Worldwide, approximately 200 million women have osteoporosis [17] defined as a value for femoral neck BMD 2.5 SD or more below the young female adult mean (T-score less than or equal to -2.5) [10]. Note that the BMD threshold applies to men as well as women.

In 2015, there were an estimated 20 million individuals with osteoporosis in the EU6. Of those, 15.8 million were women and 4.2 million were men. The number of women with osteoporosis increased markedly with age (Fig. 1). The prevalence of osteoporosis at the age of 50 years or more, as judged by femoral neck BMD, was 6.8% in men and 22.5% in women.

Country-specific estimates for individuals with the disease age 50 years or older in women ranged from 21.8% (UK) to 23.1% (Italy). For men, the number with osteoporosis ranged from 6.7% (Germany) to 7.0% (Italy). For country-specific




Fig. 2 Number (thousands) of new fragility fractures by country in 2017

details and methods, see the [Appendix](#) (1: Prevalence of osteoporosis).

Osteoporosis represents one of the greatest health risks for individuals age 50 years or more, even when compared to hypercholesterolaemia and hypertension (two major contributors to heart disease), which affect 54% and 44% of people age 50 years or more, respectively [18].

Number of fractures

There were estimated to be 2.7 million new fragility fractures in the EU6 in 2017—equivalent to 7332 fractures/day (or 305/h) (Table 1). Almost twice as many fractures occurred in women (66%) compared to men. Hip, vertebral and distal forearm/proximal humerus fractures accounted for 19.6, 15.5 and 17.9% of all fractures, respectively. Other fragility fractures accounted for 49% of the fracture burden.

The number of new fragility fractures in 2017 by country is shown in Fig. 2. Germany had the highest number of fractures in both men and women—approximately 765,000 incident fractures in total, predominately reflecting the large population size and comparatively high fracture incidence.

Table 1 Estimated number of incident fragility fractures in the EU6 by site in 2017

Fracture site	Women	Men	Men and women
Hip	381,732	144,738	526,470
Spine	267,194	148,089	415,283
Proximal humerus/distal forearm	303,021	175,020	478,041
Other	819,029	437,397	1,256,426
All	1,770,976	905,244	2,676,220

Table 2 The number of new fragility fractures in 2017 in men and women by country, the population at risk (men and women aged 50 years or more) and the crude incidence (/1000 of the population)

Country	New fractures (000)	Population at risk (000)	Rate/1000
France	381.6	24,672	15
Germany	764.9	33,399	23
Italy	563.4	26,282	21
Spain	327.6	16,510	20
UK	519.0	24,048	22
Sweden	119.7	3787	32
EU6	2676.2	128,699	21

When fracture numbers were expressed as a rate of the population at risk, there was a greater than two-fold range in risk that varied from 15/1000 in France to 32/1000 in Sweden (Table 2).

A detailed breakdown of number of fractures by site and country is given together with the methods in the Appendix (2: Lifetime risk of fragility fractures).

Lifetime risk of fragility fracture

The remaining lifetime risk of sustaining a hip fracture for women at the age of 50 years varied between 9.8% for Spain to 22.8% for Sweden (Fig. 3). The corresponding risk range for men was 6.1% (France) to 13.7% (Sweden). The lifetime risk of hip fracture at age 50 years was comparable to the lifetime risk of a stroke in Europe for both women (20%) and men (14%) [22].

The remaining lifetime probability of a MOF was highest in Sweden (46.3% for women and 28.7% for men (Fig. 4). Lifetime risk of major osteoporotic fracture was comparable to that of cardiovascular disease (CVD)




Fig. 3 Lifetime risk of hip fracture from the age of 50 years, by country and sex, and the equivalent risk for stroke




Fig. 4 Lifetime risk of fragility fracture from the age of 50 years, by country and sex, and the equivalent risk for cardiovascular disease (CVD). Source: National fracture incidences and own calculations

in Europe, which affects 29% of women and 38% of men [19]. For methods and numerical data by fracture site and country, see the Appendix (2: Lifetime risk of fragility fractures).

Fracture projections

There is a marked difference in the risk of fracture between countries [20]. Northern European countries have the highest fracture rates observed worldwide. The reasons for the difference in fracture risk are unknown but cannot be explained by differences in bone density. Plausible factors include differences in body mass index, low calcium intake, reduced sunlight exposure and perhaps the most crucial factor, high socioeconomic status, which in turn may be related to low levels of physical activity [21, 22]. Regardless of differences in fracture risk, the number of fractures in all countries is expected to increase due to an increasingly ageing population.

To estimate the annual number of new fractures between 2017 and 2030, national data on fracture incidence by type and sex were combined with demographic projections over time (see Appendix, 3: Fracture projections). The total number of all fragility fractures in the EU6 is projected to increase from 2.7 million in the year 2017 to 3.3 million in 2030; an increase of 23.3% (Fig. 5). In total, 66.2% of fragility fractures were sustained by women in 2017. The total number of MOF was 1.4 million and expected to increase by 24%. For hip fracture ($n = 526$ thousand) and clinical spine fracture ($n = 416$ thousand), the increases projected were 28% and 23%, respectively.

Variations in projections were seen between countries (Fig. 6). For example, the highest percentage increase in all osteoporotic fractures was noted in Spain (28.8%) and the lowest in Germany (18.5%), due to differences in




Fig. 5 Estimated number of fragility fractures by fracture category in 2017 and 2030. Numbers denote the percentage change for all fragility fractures, major osteoporotic fractures (MOF), hip and clinical spine fractures

projected populations over time up to 2030. Country-specific details for hip, vertebral fractures and MOFs are given in the [Appendix \(3: Fracture projections\)](#).

Imminent risk of fracture

Individuals who have already suffered a fragility fracture are at a greater risk for further fractures both at the same site and elsewhere. This additional risk of refracture is highest immediately after a fracture [23]. Figure 7 shows the risk per 100,000 women at the age of 75 years following a MOF. The high subsequent fracture risk observed during the first two years following the fracture has been referred to as the period of imminent risk [23, 24]. The existence of an imminent risk period signals that there is an opportunity to optimize the benefits of fracture prevention treatments if patients could be identified and managed as soon as possible after fracture.




Fig. 6 Number of fragility fractures by country in the EU6 and the projected numbers in 2030

Available evidence shows that similar patterns of imminent fracture risk are observed in all countries where this has been explored [25–31]. However, there is little information to assess whether there are differences in imminent fracture risk between countries. Findings from Sweden are given in the [Appendix \(4: Imminent fracture risk\)](#).

The empirical 10-year probability of MOF was consistently higher in those with a sentinel clinical vertebral fracture within the past two years than the FRAX probability in the population of the same age with any previous fracture, but the relative risk (observed/expected probability) varied by age. For example, the relative risk at the age of 50 years for a woman with a clinical vertebral fracture within the previous 2 years was 2.5; for the age of 80 years, the ratio was 1.2 (Table 3).

The impact of the adjustment in the EU6 countries is illustrated in Table 4 which shows the impact of a recent clinical vertebral fracture on conventional FRAX probabilities.

Thus, 10-year FRAX probabilities can be adjusted in the presence of a recent vertebral fracture and are likely to be useful in treatment decision-making. Similar adjustments for recent fractures at other sites are a requirement for the future.

Economic cost of fragility fractures

Fracture costs and length of hospital stay

Fragility fractures incur both short-term and long-term costs for the health care sector and for society. These costs differ between fracture sites, and to some extent reflect the severity of fracture, in particular the need for hospital




Fig. 7 Risk per 100,000 (95%CI) of a second MOF after a first MOF for a woman at the age of 75 years at her first fracture [23]. The dashed line represents the risk of first MOF in the age- and sex-matched population

Table 3 Ten-year probability of a major osteoporotic fracture (MOF) for Icelandic women at different ages, categorized by previous fracture [32]

Age	10-year probability of MOF		Ratio
	Cohort with clinical vertebral fracture 0–2 years ago	Cohort with any previous fracture in adult life	
50	29.0	11.7	2.47
60	36.1	19.4	1.86
70	41.9	27.6	1.52
80	42.5	34.2	1.24
90	34.7	33.3	1.04

admission. Hip fractures are the most severe fracture site, and almost always lead to hospitalization and high costs. The length-of-hospital-stay is an important cost component and, within country, has also been shown to have implications for how patients fare over their remaining life time [33].

In the EU6, the average length-of-hospital-stay for hip fracture ranged from 11.6 days in Sweden, to 20.5 days in the UK (Table 5). Methods are given in the Appendix (5: Length of hospital stay).

The unit fracture costs differed substantially between countries and fracture sites (Table 6). Hip fractures were the costliest fracture type in all countries, whilst distal forearm fractures were the least costly. Fracture costs were generally high in Sweden and Germany, and the lowest in Spain. For more details, see the Appendix (6: Fracture-related costs).

Annual fracture-related costs

If current trends in fracture prevention continue, as the general population grows and lives for longer, the hospital and societal cost of fragility fractures will continue to increase.

Table 4 Ten-year probability of a major osteoporotic fracture (MOF) in women with a prior clinical vertebral fracture at an undetermined time and within the past two years according to country. Age set to 60 years, BMI 25 kg/m², no additional risk factors [32]

Country	Probability MOF (%)	
	Undetermined time	Within the past 2 years
France	9.4	17
Germany	12	22
Italy	12	22
Spain	7.0	13
Sweden	21	39
UK	16	30

The fracture-related costs in the EU6 amounted to €37.5 billion in the year 2017. Hip fractures accounted for the majority of the total cost (57%) whereas they accounted for 20% of fragility fractures (Fig. 8).

The direct cost of fractures in each EU6 country is given in Table 7. Costs comprise the annual cost of fractures in 2017 (incident fractures), those arising from fractures before 2017 (prior fractures) and the cost of institutional care.

In 2010, fracture-related costs in the EU6 were estimated to total €29.6 billion [39]. Fracture-related costs for the EU6 in 2017 were now estimated to total €37.5 billion (an increase of 27% since 2010), and are projected to increase to €47.4 billion in 2030 (an increase of 27% since 2017) (Fig. 9).

As expected, costs will increase due to the increase in fracture cases. The fracture-related costs in the EU6 are projected to increase by 27% from a total €37.5 billion in the year 2017 to €47.4 billion in 2030. Cost projections to 2030 are shown for each country by fracture site in Fig. 10. The dominant cost was for hip fracture. The fracture-related cost estimates provided are conservative, since costs from other fracture sites were not included in the estimation.

There were small variations in the percentage increase in cost by country. The greater increases were noted in Spain

Table 5 Mean length of hospital stay (LOS) and standard deviation (SD) following a hip fracture

Country	LOS (days)		Source
	Mean	SD	
France	12	8.0	[34]
Germany	14.5 (2.6)	2.6	[35]
Italy	19.0 (25.3)	25.3	[36]
Spain	11.8 (7.9)	7.9	[37]
Sweden	11.6 (8.7)	8.7	[33]
UK	20.5 (20.0)	21.6	[38]

Table 6 Mean cost of fracture (€ 2017) in the year following fracture at the sites shown

Country	Hip	Vertebral	Distal forearm
France	12,856	3205	1468
Germany	20,884	11,080	1275
Italy	21,307	4713	1301
Spain	9724	1928	533
Sweden	16,406	14,474	4028
UK	20,650	4028	2568

(+30.6%), the UK (+30.2) and Sweden (+29.4%) and lower increments in Germany (+23.2%), Italy (+26.2%) and France (+26.4%).

Cost for incident fractures in a given year and long-term cost (due to fractures that arose in previous years), as well as the cost of residing in nursing homes, are detailed in the [Appendix \(7: Annual cost of fractures\)](#).

Table 7 The direct cost (million Euro) of fractures in 2017 (incident fractures), those arising from fractures before 2017 (prior fractures) and the cost of institutional care in each EU6 country

Country	Incident fractures	Prior fractures	Institutional care	Total
France	3748	219	1404	5371
Germany	8176	414	2680	11,270
Italy	5951	299	3179	9429
Spain	2150	137	1915	4202
UK	2955	372	1919	5246
Sweden	1199	81	690	1970

Patient burden

Quality-adjusted life years

The use of QALYs is a method of measuring the burden of a disease where a year of an individual’s life is weighted by the average health-related quality of life (HRQoL) that a person had during that year. For example, 1 QALY is equal to one year spent in perfect health; 0.5 QALYs can be thought of as either half a year spent in perfect health followed by death, or one year lived at 50% of perfect health. QALYs are regularly used in economic analyses because they provide decision makers with a method for quantifying and comparing burden across diseases.

QALYs lost due to fragility fractures were estimated from fracture-based HRQoL, fracture risks and death rates [40–42]. Methods are summarised in the [Appendix \(8: Quality-adjusted life years\)](#). Estimates of the QALY loss were generated from 2017 up to year 2030, based on population projections, to show the expected change in QALY loss for the near future.




Fig. 8 Number and cost of fragility fractures in the EU6 expressed as a percentage of the totals. Note: The estimates conservatively assume no long-term costs for ‘other fractures’




Fig. 9 Annual cost of fractures by site in the EU6 for 2017 and projected increase by 2030




Fig. 10 Cost of fragility fractures in 2017 and that expected in 2030 by country and fracture site

The total health burden in 2017 due to fragility fractures in EU6 was at 1.02 million QALYs. 66% of the QALY loss was due to fractures occurring in women. The QALY loss in absolute numbers was highest in Germany due to the size of the population combined with comparatively high risk of fractures. The lowest QALY loss was observed in Sweden due to the small population size compared to the other countries. On a per capita basis, Sweden had the largest burden (4.22 lost QALYs per 1000 people age 50 years and above) and France the lowest (2.11 lost QALYs per 1000) (Fig. 11). The differences were driven, in large part, by differences in the risk of fractures and age distribution between countries.

The QALY burden is expected to increase by 25.6% in the year 2030 but varied by country (Fig. 12).

Disability-adjusted life years

The DALY (or disability-adjusted life year) is the World Health Organization’s (WHO) standard method of measuring the burden of a disease. DALYs are the sum of years of life lost (YLL) and the years lost due to




Fig. 11 Quality of life years (QALYs) lost in 2017 due to fragility fractures per 1000 of the population age 50 years or more in countries of the EU6




Fig. 12 Quality of life years (QALYs) lost due to fragility fractures in countries of the EU6 in 2017 and 2030

disability (YLD) [46]. A single DALY can be thought of as one year of ‘healthy life’ lost. Summing the DALYs across an entire population provides the gap between the current health status of a population and an ideal disease-free population, i.e. the burden [43]. Including this measure of burden allows for comparison of the burden of different diseases, both within and between countries.

When using the WHO standard method, the total DALYs related to fragility fractures in year 2016 for the EU6 (ages of 50 to 100 years) were more than 2.6 million DALYs. Average YLDs per 1000 people (15.1) far exceeded the YLLs per 1000 (5.5), indicating that living with a disability due to fracture drives DALY loss in osteoporosis.

The DALY burden was less for hip fracture than for vertebral fracture which, in turn was less than for other fragility fractures (Fig. 13). This dominance of other fragility fractures over hip fractures arose from the combination of a high incidence at early ages, and the large number of years spent with disability from other fractures compared with hip fracture.




Fig. 13 Total DALY distribution by fracture site




Fig. 14 Total DALYs by age for hip fractures in women

The age distributions of YLLs and YLDs differed by fracture site. In women with hip fractures (Fig. 14), the YLLs peaked at the age of 77 years, whilst the YLDs peaked at age 81 years, reflecting that most hip fractures occur around 77 years. The YLDs for non-hip, non-vertebral fractures in the female population (Fig. 15), peaked early and was sustained over age, with very low YLLs, indicating that prevalence of non-hip, non-vertebral (NHNV) fractures is high but with limited consequences for mortality when compared with that following hip fracture. The equivalent data for men are given in the [Appendix \(9: Disability-Adjusted life years\)](#).

The total DALY for each country varied greatly due to differences in population demography and fracture risk (Fig. 16). The average DALY loss per 1000 individuals was estimated to be 21 DALYs, with Sweden showing the highest rate (32 DALYs) and Spain showing the lowest (12 DALYs).




Fig. 15 Total DALYs by age for non-hip, non-vertebral (NHNV) fractures in women

The DALYs related to fragility fractures can be compared to corresponding estimates for other diseases. In Fig. 17, fragility fracture-related DALYs are compared to 16 other common non-communicable diseases in the EU6 [44]. Among these, fragility fractures are placed as the fourth most burdensome, outranked only by ischemic heart disease, dementia and lung cancer.

The DALY burden by disease category varied between countries due to differences in age distribution, risk of fracture and death. The DALY burden also varied by disease category. In Sweden, for example, the DALY burden of fractures was higher than that for dementia whereas in Spain the burden related to dementia, lung cancer and COPD surpassed that for fractures. For more details, see the [Appendix \(9: Disability-adjusted life years and 11: DALY comparison across diseases\)](#). The metrics also provide details of the DALY distribution by fracture site.

From a national perspective, the DALY loss rate can be an important measure for motivating policy decisions and the prioritization of funds towards osteoporosis treatment. From an international perspective, the high values suggest a need for better treatment policy and practice.


Loss of productivity

Most fragility fractures occur in older retired patients. If, however, individuals sustain a fracture whilst still employed they will likely need to take time off from work to recover from the fragility fracture. In Sweden, for example, about 20% of fractures occur at pre-retirement age [11]. Work absence both impacts the individual's income and creates a societal cost due to the loss of productivity.

To measure this loss of productivity, data collected in the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS) [41, 45, 46] were used to estimate the number of sick days taken by non-retired individuals from the ages of 50 to 65 years in the year following an osteoporotic fracture. Since Germany was not included in the 11 countries that made up the ICUROS study, a combination of the other 5 countries, as well as Austria and Estonia, termed ICUROS Europe, was used as a substitute measure for the EU6. Average sick days were combined with fracture projection data to estimate the total sick days taken due to fragility fractures in 2017, by non-retired individuals. Because there are no appropriate data on the proportion of the population that work beyond the age of 65 years, a retirement age was set at 65 years for all countries in the calculations. For more details, see [Appendix \(11: Productivity loss\)](#).

Hip fractures resulted in the highest number of sick days taken in the first year after fracture (42 days), followed by vertebral fractures (20 days) and other

Fig. 16 Total DALYs by country (left panel) and DALYs per 1000 individuals by country (right panel)



MOFs (12 days). Sick days taken in 2017, by non-retired individuals in the EU6 totalled 7,615,719 days. The other MOFs (distal forearm and proximal humerus fracture) arose more often than hip or clinical vertebral fractures, and therefore resulted in the highest number of sick days.

When sick days taken due to fragility fracture were expressed per 1000 people age 50 to 65 years in all countries, Sweden had the highest estimate of the EU6 countries (Fig. 18). There were no significant differences between sick leave taken by men and women with hip fractures, nor between sick leave taken by hip fracture patients with or without previous fracture.

Caregiver burden

Another significant burden associated with fragility fractures and other diseases is the burden imposed on informal

caregivers such as family members. Continued care provided at home can put physical, emotional and financial strain on relatives who need to take care of osteoporotic fracture patients [15, 47]. To measure the average burden placed on informal caregivers per year, survey responses from the ICUROS [41, 45, 46] were also used to determine the caregiver burden due to osteoporotic fracture. It was measured in terms of hours of care per year provided by relatives of fracture cases in ICUROS Europe (a substitute measure for the EU6), as well as selected countries. For methods and estimates by fracture type, see the Appendix (12: Caregiver burden).

Hip fractures were associated with the largest caregiver burden (370 h per year), followed by vertebral fractures (263 h per year) and other MOFs (130 h per year). Hours of care provided by relatives varied greatly by country. In countries where cross-generational support is more established, the impact of fragility fractures on caregivers is generally higher [48]. Accordingly, Spain and Italy had the highest caregiver burden, with averages of 756 h and 882 h a year, per 1000 individuals, spent caring for patients with osteoporotic hip




Fig. 17 DALYs by disease in EU6 in 17 selected non-communicable diseases




Fig. 18 Average sick days taken after fragility fracture per 1000 individuals' age 50–65 years, by country




Fig. 19 Average annual hours of care by relatives after hip fracture by country

fractures, respectively. France (138 h) and Sweden (191 h) had considerably lower averages (Fig. 19). There were no significant differences in care from relatives between men and women, nor between patients with or without a previous fracture.

Independent living

One major burden caused by fragility fractures is the long-term impact on independence. The fracture can result in a loss of mobility, the ability to take care of oneself, and may require the individual to move into long-term care (LTC) or care services [49]. The ICUROS provided survey responses for the percentage of individuals who needed to move into LTC as a direct result of an osteoporotic fracture. For methods, see the Appendix (13: Independent living).

LTC use varied greatly, depending on the fragility fracture and the age of the individual. Hip fractures result in the largest




Fig. 20 Percentage of patients admitted to long-term care (LTC) within 12 months after a fracture by fracture site (ICUROS Europe). Other refers to other fragility fractures




Fig. 21 Percentage in long-term care (LTC) at one year after hip fracture, by age group

proportion of people moving to LTC in ICUROS Europe (Fig. 20).

The percentage of patients moving into LTC following a hip fracture increased significantly with age, from 2.1% at ages 50–60 years to 35.3% at ages 90–100 years (Fig. 21).

Fracture prevention

Pharmacological treatment gap

The treatment gap (i.e. the number of women that are treated compared to the proportion of the population that could be considered eligible for treatment) in osteoporosis has been estimated for the European Union using international sales data on volume (standard units) and price (€) from IMS Health for year 2010 [15, 50]. Applying the same methodology, an update of the treatment gap was conducted using IMS sales data for year 2017. The analysis included data on sales




Fig. 22 Treatment gap in men and women by country in 2017




Fig. 23 The treatment gap (percent eligible patients not treated) in men from the EU6 in 2010 and 2017

related to all osteoporosis drugs (bisphosphonates, denosumab, parathyroid hormone and peptides, selective oestrogen receptor modulators (SERMs) and strontium ranelate). Menopausal hormone treatment (MHT) was not included.

The treatment gap was estimated from the difference between the number of patients treated with an osteoporosis drug using IMS sales data and the number of patients in the population considered to be eligible for an osteoporosis treatment. Further details are given in the Appendix (14: Pharmacological treatment gap). In line with European guidelines [51], patients eligible for treatment have a country- and age-specific MOF fracture probability equivalent to a woman with a prior fragility fracture based on the FRAX algorithm. The calculation of the treatment gap assumes that all treatments are given to patients above the intervention threshold. The approach does not take account of differences in treatment guidelines between countries.

The average treatment gap (percent eligible patients not treated) in EU6 in year 2017 was 73% for women and 63% for men (Fig. 22). The higher gap in women was the case in all countries with the exception of Germany which had the




Fig. 24 The treatment gap (percent eligible patients not treated) in women from the EU6 in 2010 and 2017




Fig. 25 Percentage (%) of women (50 years and above) not treated within a year of an osteoporotic fracture or a hip fracture

highest treatment gap. Only 20% of eligible men and 22% of women in Germany would receive a pharmacologic intervention. The treatment gap varied between countries. The highest treatment gap for women was in Germany, whereas the UK had the smallest treatment gap (64%) in women and men (43%).

Changes in the treatment gap between 2010 and 2017 are shown for men (Fig. 23) and women (Fig. 24). Compared to the analysis from year 2010, there was a marked increase in the treatment gap for the EU6 (17% and 16% points for women and men, respectively). This increase was mainly driven by large changes in France and Spain. The adverse changes in treatment gap were most marked in France (38 percentage points increase in men and 34 percentage points in women), and Spain (by 40 and 43 percentage points increase in men and women, respectively). The treatment gap increased to a lesser extent in Italy and was relatively stable in Germany, Sweden and the UK.




Fig. 26 Percentage of women untreated within one year of fracture by site of fracture and prior exposure to osteoporosis treatment in Sweden. N, treatment-naïve; E, prior exposure




Fig. 27 Percentage of men untreated within one year of fracture by site of fracture and prior exposure to osteoporosis treatment in Sweden. N, treatment-naïve; E, prior exposure

Post-fracture treatment gap

An alternative approach for assessing the treatment gap is to estimate the proportion of patients starting a pharmacological treatment after a fracture. Available estimates were gathered from a mix of literature, public reports (France [52] and the UK [53]), data on file at UCB (Spain) and data on file at Quantify Research (Sweden). The percentage of women who did not receive osteoporosis-specific pharmacological treatment within a year of an osteoporotic fracture is shown in Fig. 25. The analytic methods vary between the estimates making direct comparisons difficult. However, the post-fracture treatment gap can be considered large irrespective of country. With the exception of the UK, no more than 30% of women receive a treatment following a fracture. In the UK, the treatment gap was markedly lower after hip fracture (49%). For more details, see the Appendix (15: Fracture treatment gap).

A more detailed analysis, using the Swedish National Patient Register (NPR) and the Swedish National Prescription Register, was conducted to explore differences in the treatment gap for different subpopulations. Patients were defined as treatment-naïve if they had not collected any prescriptions for anti-osteoporotic medications during the three years prior to the fracture.




Fig. 28 FRAX calculations by URL source per million in the general population November 2010–October 2011 and April 2017–March 2018

At the time of fracture, most women (89%) and men (97%) were treatment naïve. Figure 26 shows the pattern of treatment following a fracture by treatment exposure in women. Within the year following a hip fracture, a MOF or any fragility fracture, only 11% to 12% of treatment-naïve women started treatment for osteoporosis. Following a vertebral fracture, 26% of treatment-naïve women started treatment. A similar pattern was observed in the male population although treatment gaps were in general higher (Fig. 27). About 5% of treatment-naïve men were treated following a hip fracture, or a MOF. Following a vertebral fracture, 11% of treatment-naïve men started treatment.

In men and women who had previously been exposed to therapies for osteoporosis, the treatment gap was substantially lower than in treatment-naïve patients. These findings illustrate important issues in that a new treatment is rarely offered to (or taken up by) patients after fracture and, even in patients previously exposed to osteoporosis treatment, only about half receive a treatment within the next year.

A limitation of this analysis is that the Swedish National Patient Register (SNPR) does not cover drugs dispensed at the hospital (mainly intravenous and subcutaneous administered medications), which are estimated to comprise 4% of medicines sold [54]. This likely leads to a slight overestimation of the treatment gap. For more details, see the Appendix (16: Treatment gap by fracture type).

Table 8 Risk models and guidelines available in the countries of interest

Countries	FRAX model available	Other models	National guidance	Comments	Source
France	Yes	–	Yes		[63]
Germany	Yes	DVO Model	Yes		[59]
Italy	Yes	FRAHS, DeFra	Yes	FRAHS: FRAX-based	[64–66]
Spain	Yes	–	Yes		[67]
Sweden	Yes	–	Yes		[68]
UK	Yes	QFracture	Yes		[69]

Table 9 Meta-analysis results for outcomes of FLS [78]

Outcome measure	Effect of FLS (absolute change)	95% CI	Duration of follow-up (months)	Number of studies
BMD testing	+24%	(0.18 to 0.29)	3–26	37
Treatment initiation	+20%	(0.16 to 0.25)	3–72	46
Adherence	+22%	(0.13 to 0.31)	3–48	9
Refraction	–5%	(–0.08 to –0.03)	6–72	11

Fracture risk assessment

Although osteoporosis is defined in terms of BMD, there are several other factors that are associated with an increased risk of fracture that are not captured by BMD. This has led to the development of risk models, which incorporate several risk factors to improve the identification of patients at high risk [55].

There are several existing models for risk assessment in Europe; however, the most widely used is FRAX [56]. FRAX, released in 2008, is a computer-based algorithm that calculates the probability of fracture in individuals using age, body mass index, BMD (optionally) and risk factors such as whether the patient had a prior fragility fracture, their parental history of hip fracture, whether they smoke, drink, have rheumatoid arthritis and other factors that increase the risk for osteoporosis [57]. FRAX models are currently available for 68 countries and are publicly available on the official FRAX website [58]. There are also several other fracture risk assessment models available.

Table 8 provides a summary of the access to FRAX and other risk assessment models in the EU6. Country-specific FRAX models exist in all 6 countries. Alternative assessment models are also recommended for use in Germany, Italy and the UK. The German DVO model, developed in 2006, is a Germany-specific risk assessment model which requires the use of BMD measurements [59, 60]. DeFra is an Italy-specific extension of the FRAX model, which allows for comparison of the BMD in different fracture sites and the inclusion of more variables [61]. QFracture® in the UK was developed in 2009, and uses variables that are available through healthcare records in the UK; it does not include BMD [62]. For more details, see the Appendix (18: Fracture risk assessment).

Specific guidelines for the use of FRAX and other risk models are noted on official national health service websites for all countries except for Italy. The Italian Ministry of health does not recommend specific risk models but suggests that risk models may be useful in assessing the probability of fragility fracture. Other organizations like the Italian Society for Orthopaedics and Traumatology recommended FRAX or DeFra.

The uptake of FRAX in 2010 and 2017 is shown in Fig. 28 as the number of calculations/million persons in the general population. The UK and Sweden had the highest usage of FRAX, whereas the lowest uptakes were seen in Germany and Italy. Considering all countries in the EU6, the usage of FRAX increased by almost 74% in 2017 compared to 2010. The highest increase was seen in the UK, France and Sweden (~100%), whereas in both Germany and Italy, the usage of FRAX decreased was reduced in 2017 compared to 2010. In both Germany and Italy, the usage of FRAX decreased in 2017 compared to 2011. The decrease in the use of FRAX in both Italy and Germany may relate to the availability of other risk models such as the German specific DVO model and DeFra in Italy. For more details, see the Appendix (18: Use of FRAX).

Fracture liaison services

A fracture liaison service (FLS) is a multi-disciplinary health care delivery model for secondary fracture prevention. FLS aims to systemically identify, treat and refer all eligible patients within a local population who have suffered a fragility fracture with the aim of reducing their risk of subsequent fractures. The FLS concept was first introduced in teaching hospitals in Scotland and has grown in popularity around the world due to its effectiveness in preventing secondary fractures [70]. A growing body of published evidence suggests

Table 10 Country-specific studies on the economic impact of FLS

Country	Type	Estimate	Source
Sweden	ICER (cost-eff)	€ 14,029 (per QALY gained)	[79]
UK (hip patients)	ICER (cost-eff)	€22,700–€26,600 (per QALY gained)	[80]
UK	Cost savings	€23,800/lifetime/1000 patients	[74]

Table 11 Number of Capture the Fracture FLS ratings by country and scores [73]

Country	Total	Gold	Silver	Bronze	Other	Score	Score/ FLS
France	20	0	3	9	8	35	1.75
Germany	2	0	1	0	1	4	2.0
Italy	13	1	3	2	7	24	1.8
Spain	65	13	13	22	17	152	2.3
Sweden	5	0	4	1	0	14	2.8
UK	25	6	11	1	7	66	2.6
EU6	130	20	35	35	40	285	2.2

that FLSs are a cost-effective care delivery model that has the potential to reduce the risk of refracture, increase the number of high-risk patients being treated and improve adherence to treatment. [71–77].

A recently published systematic literature review and meta-analysis based on 159 scientific publications studied several important outcomes of fracture liaison services [78]. Albeit, with a variety of study designs used, all the studies attempted to estimate the impact of a FLS compared to the absence of such a program. The meta-analysis indicated that FLS improved the rate of fractured patients getting BMD tests, starting treatment and adhering to treatment by about 20% (Table 9). The results also showed a significant reduction in the refracture rates.

Even though the meta-analysis showed an overall positive impact of FLSs, it did not consider that there are different types of FLS models which is likely to be associated with different outcomes. For example, some FLS only identify patients and inform them without taking any further actions whereas other more complete FLS identify, investigate, treat and monitor the patient. In another recent study, the evidence of different FLS model types (A to D) on fracture risk, DXA referrals, and other patient outcomes were reviewed [77]. The most complete FLS model (type A) was associated with reduction in refracture risk (hazard ratio [HR] 0.18–0.67 over 2–4 years), increased assessment of BMD (relative risk [RR] 2–

3), increased treatment initiation (RR 1.5–4.25) and adherence to treatment (65–88% at 1 year).

Along with the literature focusing on the impact of FLSs, several studies have analysed the cost-effectiveness and cost savings of providing FLSs. Estimates in Sweden and the UK for the economic impact of FLSs are shown in Table 10. For more details, see the Appendix (19: Fracture liaison service impact).

The large variation between different types of FLS and their evaluation complicates the assessment of the overall benefits of FLS and merits of a specific FLS model. Initiatives that promote standardised outcome frameworks for assessing FLS and increased collaboration between providers include the Capture the Fracture® and the UK FLS-Database Audit [81, 82].

Capture the Fracture®

One effort to encourage cooperation between FLS providers is *Capture the Fracture®* (CtF), a global initiative of IOF to ‘facilitate the implementation of coordinated, multi-disciplinary models of care for secondary fracture prevention’ [73]. CtF has created a set of internationally endorsed standards and guides for best practice and has assembled the largest network of individual FLS providers in the world. CtF provides resources, tools and educational programmes to bridge the gap between FLS providers and helps in the creation of new FLS.

This growing network of FLS providers is mapped on their website (<https://www.capturethefracture.org/map-of-best-practice-page>)spain and provides a rating of the existing service providers in a given area. To be included in the CtF network, the provider must undergo a standardised external audit to determine the quality of their services. Table 11 shows the star ratings for registered FLS providers in the countries of interest. A value of 4, 3 and 2 was applied to gold, silver and bronze, respectively and a 1 to providers currently under review. Spain and the UK lead in terms of the number of registered FLS, whereas Spain, the UK and Sweden score highly in the average score/FLS.

Table 12 Potential reduced burden by closing the FLS gap

Country	Fractures avoided (per year)	Fractures avoided per 1000 FLS patients	Reduction in annual fracture-related cost (million €)	Net impact on annual burden (million €)	Net impact per patient (€)	Reduction in annual burden (QALYs)
France	2665	10.0	–38.0	20.0	75.0	1036
Germany	5423	13.9	–75.4	8.2	21.0	2335
Italy	2868	7.2	–55.7	–4.8	–12.0	1602
Spain	1249	5.4	–18.4	20.0	86.0	584
Sweden	1371	22.7	–22.4	–2.3	–38.0	596
UK	5686	16.2	–75.5	–1.4	–4.0	2705
EU6	19,262	11.3	–285.4	39.7	16.2	8858

There is currently no publicly available information on how many fragility fractures are referred to an FLS within the EU6 countries. A survey sent to a selected number of FLSs in the EU6, enrolled in IOF's *Capture the Fracture* network, asked for the percentage of hospitals and general practitioners (GPs), on a national level, that have a system to refer fractured patients. The responses varied between an average of 2.8% in Italy, to 37.5% in Sweden for hospital referrals and 1–10% for GP referrals. In the UK, the National Osteoporosis Society has estimated that 55% of the UK population has access to a FLS. For more details, see the [Appendix \(20: Capture the fracture\)](#).

Closing the FLS gap

Given the available evidence showing the potential benefits of FLSs and the sub optimal coverage of such models in the EU6, it is as relevant to highlight the FLS treatment gap. When applying the information on fracture epidemiology, costs, current FLS coverage previously described in this report and evidence of FLS outcomes based on Wu et al. [78], it is possible to assess the potential impact a complete coverage of FLS could have on the burden of fragility fractures.

It is estimated that, 19,262 number of subsequent fragility fractures could be avoided every year by extending the access to FLS for all citizens above 50 years of age in EU6. The reduction in the annual fracture-related cost associated with these fractures is €285.4 million. Adding the additional cost related to increased FLS resources and drug administration the net impact is an increased cost of €39.7 million but at a gain of 8858 quality-adjusted life years (Table 12). The cost per QALY gained of an FLS extension would be €3108, an estimate that can be considered cost-effective in all countries and probably underestimated because of conservative assumptions on the costs related to other osteoporotic fractures. The variation between countries is mainly driven by differences in fracture risk and cost of osteoporosis drugs.

Executive summary

Osteoporosis is a disease that weakens the bones and increases the risk of fragility fractures, where bones can break from a fall from a standing height or less. In Western Europe, about 1 in 3 women and 1 in 5 men at or above the age of 50 years will fracture during their lifetime. The number of fragility fractures and cases of osteoporosis is increasing worldwide, creating an increasing burden to society.

This report provides an overview and a comparison of the burden and management of fragility fractures in six European

countries (France, Germany, Italy, Spain, Sweden, UK), hereafter referred to as EU6.

Key findings

- The total number of fragility fractures in the EU6 is estimated to increase from 2.7 million in 2017 to 3.3 million in 2030; an increase of 23.3%.
- The annual fracture-related costs in the EU6 are projected to increase from a total €37.5 billion 2017 to €47.4 billion in 2030; an increase of 27%.
- The number of disability-adjusted life years (DALYs) per 1000 individuals' age 50 years or more in EU6 due to fragility fractures was estimated at 21 years. This is a higher estimate compared to some other chronic diseases such as stroke (13 DALYs per 1000) and chronic obstructive pulmonary disease (COPD) (15 DALYs per 1000).
- The risk of refracture is highest immediately after a fracture. This has been referred to as the period of imminent risk; this phenomenon suggests that there is an opportunity to optimize the benefits of fracture prevention by treating patients as soon as possible after occurrence of a fracture.
- The treatment gap (defined as the percent eligible individuals not receiving treatment with osteoporosis drugs) in EU6 in year 2017 is estimated to be 73% for women and 63% for men. Compared to analysis from the year 2010, this is a marked increase from 56% in women and 47% in men.
- The proportion of patients starting a pharmacological treatment in the year after a fracture is low. In France, Sweden and Spain, 85%, 84% and 72% of fracture patients remained untreated 1 year after fracture, respectively.
- A fracture liaison service (FLS) is a multi-disciplinary health care delivery model for secondary fracture prevention. This health care delivery model has become more common in recent years, but its coverage is still low.
- A growing body of evidence suggests that FLS are cost-effective care delivery models that have the potential to increase the number of high-risk patients being treated, improve adherence to treatment and reduce the risk of refracture.
- A FLS provides an opportunity to improve early post-fracture patient identification and reduce the treatment gap.
- If FLS could be further expanded to reach all fracture patients in the EU6, 19,262 additional fractures every year would be avoided, and fracture-related costs would be reduced by €285.5 million.

Key results by country

Key Results (mean values*)	France	Germany	Italy	Spain	Sweden	UK	EU6
Lifetime risk of hip fracture in women from age 50	11.0%	17.1%	16.7%	9.8%	22.8%	17.2%	15.1%
Percentage increase in fragility fractures by 2030	24.4%	18.5%	22.4%	28.8%	26.6%	26.2%	23.3%
Annual fracture related cost per capita (€)	83	137	159	91	199	79	114
Percentage increase in fracture related costs by 2030	26.4%	23.2%	26.2%	30.6%	29.4%	30.2%	27.7%
Percentage increase in Quality-Adjusted Life-Years (QALYs) lost by 2030	26.4%	22.4%	24.7%	29.8%	27.2%	28.2%	25.6%
Fracture related Disability-Adjusted Life-Years (DALYs) per 1,000 people	17	24	20	12	32	24	21
Fracture related sick days per 1,000 people	16	32	24	15	36	21	24
Relative care hours related to fractures per 1,000 people	138	-	882	756	191	248	443
Overall treatment gap in women (%)	77%	78%	73%	68%	76%	64%	73%
Post fracture treatment gap in women (%) - osteoporotic fracture	85%	-	-	72%	84%	-	72%-85%
Post fracture treatment gap in women (%) - hip fracture	-	-	-	68%	84%	49%	49%-84%
FRAX model with guideline available (yes/no)	YES	NO ⁺	YES	YES	YES	YES	NA
Change in the uptake of FRAX from 2010 to 2017 (%)	+100%	-6%	-16%	+17%	+118%	+99%	+75%
Number of fracture liaison services (FLS) enrolled in the Capture the Fracture (CtF) network (total)	15	3	12	54	5	17	106
Potential reduction in number of fragility fractures (per 1,000 population) with improved coverage of FLS	10.0	13.9	7.2	5.4	22.7	16.2	11.3
Potential reduction in fracture related costs (€) (per 1,000 of new FLS patients) with improved coverage of FLS	-143	-193	-139	-79	-370	-216	-168

*Mean value if not otherwise stated

⁺FRAX is available in Germany, but no guideline currently endorses its use

Colours indicate ranking among countries (from green = best to red = worst)

Acknowledgements We are grateful to the consultation panel, for their review of the country-specific metrics. International Osteoporosis Foundation: Cyrus Cooper, President; Jean-Yves Reginster, Chairman Committee of National Societies; Serge Ferrari, Chairman Committee of Scientific Advisors; Philippe Halbout, Chief Executive Officer.

Consultation panel

France

Bernard Cortet University Hospital Lille, France
Thierry Thomas Rheumatology Department, University Hospital St. Etienne, France
Laurent Grange Department of Rheumatology, University Hospital Grenoble, France

Germany

Claus Glüer Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Kiel University, Germany
Andreas Kurth Department of Traumatology, Orthopedics and Hand Surgery, Community Hospital Mittelrhein gGmbH, Germany
Peyman Hadji Department of Bone Oncology, Endocrinology and Reproductive Medicine, Krankenhaus Nordwest, Germany
Thorsten Freikamp Federal Self-help Association for Osteoporosis (BfO), Germany

Italy

Maria Luisa Brandi Department of Endocrinology and Metabolic Diseases and Director of the Operative Unit of Diseases of Mineral and Bone Metabolism, Medical School, University of Florence, Italy
Stefano Gonnelli Department of Internal Medicine and Director of the School of Specialization in Emergency Medicine and Urgency, University of Siena, Italy
Giuseppe Sessa Department of Orthopedics and Traumatology and Orthopedic Clinic of the Vittorio Emanuele Polyclinic, University of Catania, Italy

Spain

Josep Blanch Rubio Department of the Institut Blanch de Reumatologia, Spain
Adolfo Diez-Perez Department of Internal Medicine at the Hospital del Mar, Autonomous University of Barcelona, Spain
Maria A Robles Palacios Asociación Española con la Osteoporosis y la Artrosis, Spain

Santiago Palacios Instituto Palacios, Salud y Medicina de la Mujer, Spain

Sweden

Mattias Lorentzon Department of Geriatric Medicine, Institute of Medicine, University of Gothenburg, and Osteoporosis Clinic at the Sahlgrenska University Hospital, Sweden
Lisa Keisu Lennerlöf Osteoporosförbundet, Swedish Osteoporosis Association, Sweden

UK

Cyrus Cooper MRC Lifecourse Epidemiology Unit, University of Southampton, UK and Professor of Musculoskeletal Science at the NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, UK.
Fizz Thompson National Osteoporosis Society, UK
Celia L Gregson Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, UK

International Osteoporosis Foundation

Cyrus Cooper President
Jean-Yves Reginster Chairman Committee of National Societies
Serge Ferrari Chairman Committee of Scientific Advisors
Philippe Halbout Chief Executive Officer

Funding information The report was made possible by the financial support from UCB to the International Osteoporosis Foundation.

Compliance with ethical standards

Conflict of interest F Borgström is employed and is a shareholder in Quantify Research. A health economic research consultancy that received a grant from IOF to conduct the analysis.

L Karlsson, G Ortsäter and N Norton are employed by Quantify Research. A health economic research consultancy that received a grant from IOF to conduct the analysis.

P Halbout has no competing interests to declare.

C Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB.

EV McCloskey has received consultancy/lecture fees/grant funding/honoraria from ActiveSignal, AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Gilead, GSK, Hologic, Internis, Lilly, Medtronic, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, SanofiAventis, Servier, Synexus, Tethys, UCB, Viiv, Warner Chilcott, I3 Innovus and Unilever.

NC Harvey has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly,

Servier, Shire, UCB, Consilient Healthcare, Radius Health, Kyowa Kirin and Internis Pharma.

MK Javaid has received honoraria, unrestricted research grants, travel and/or subsistence expenses from Amgen, Lilly UK, Internis, Consilient Health, Zebra Medical Vision, Kyowa Kirin Hakin, UCB.

JA Kanis reports grants from Amgen, Eli Lilly and Radius Health; consulting fees from Theramex. JAK is the architect of FRAX® but has no financial interest.

M Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma and Consilient Health, all outside the presented work.

Metrics

The accompanying supplementay material contains the individual metrics which served as the background research and evidence for the above report. The metrics include details about the estimation and reporting methods as well as additional research and source material.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. International Osteoporosis Foundation (2018) Broken bones, broken lives: a roadmap to solve the fragility fracture crisis in Europe. International Osteoporosis Foundation, Nyon, Switzerland. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
2. International Osteoporosis Foundation (2018) Os brisés, vies brisées: une feuille de route pour résoudre la crise des fractures de fragilité en France. International Osteoporosis Foundation, Nyon, Switzerland. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
3. International Osteoporosis Foundation (2018) Ruinierte Knochen, ruiniertes Leben: Ein strategischer Plan zur Lösung der Fragilitätsfrakturkrise in Deutschland. International Osteoporosis Foundation, Nyon, Switzerland. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
4. International Osteoporosis Foundation (2018) Ossa spezzate, vite spezzate: un piano d'azione per superare l'emergenza delle fratture da fragilità in Italia. International Osteoporosis Foundation, Nyon, Switzerland. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
5. International Osteoporosis Foundation (2018) Huesos rotos, vidas rotas: guía para mejorar la atención a las fracturas por fragilidad en España. International Osteoporosis Foundation, Nyon, Switzerland. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
6. International Osteoporosis Foundation (2018) Brutna ben, trasigala liv: En åtgärdsplan för att lösa krisen med benskörhetsfrakturer i Sverige. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
7. International Osteoporosis Foundation (2018) Broken bones, broken lives: a roadmap to solve the fragility fracture crisis in the United Kingdom. International Osteoporosis Foundation, Nyon, Switzerland. <https://www.iofbonehealth.org/broken-bones-broken-lives> Accessed 09/12/2019
8. International Osteoporosis Foundation (2018) What is Osteoporosis? <https://www.iofbonehealth.org/what-is-osteoporosis> Accessed 05/03/2018
9. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltvaev N (2008) A reference standard for the description of osteoporosis. *Bone* 42:467–475
10. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltvaev N (1994) The diagnosis of osteoporosis. *J Bone Miner Res* 9:1137–1141
11. Kanis J, Johnell O, Oden A, Sernbo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. *Osteoporos Int* 11:669–674
12. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int* 12:417–427
13. Warriner AH, Patkar NM, Curtis JR, Delzell E, Gary L, Kilgore M, Saag K (2011) Which fractures are most attributable to osteoporosis? *J Clin Epidemiol* 64:46–53
14. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 17:1726–1733
15. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. *Arch Osteoporos* 8:136
16. Kanis JA (2007) Assessment of osteoporosis at the primary health care level. In WHO Scientific Group (ed) WHO Scientific group Technical Report. World Health Organization, p 103
17. Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. *Osteoporos Int* 2:285–289
18. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Katarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F (2003) Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *Jama* 289:2363–2369
19. Hippisley-Cox J, Coupland C, Robson J, Brindle P (2010) Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QRisk database. *Bmj* 341:c6624
20. Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. *Osteoporos Int* 23:2239–2256
21. Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S (2016) Major osteoporotic fragility fractures: Risk factor updates and societal impact. *World J Orthop* 7:171–181
22. Jakobsen A, Laurberg P, Vestergaard P, Andersen S (2013) Clinical risk factors for osteoporosis are common among elderly people in Nuuk, Greenland. *Int J Circumpolar Health* 72:19596
23. Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. *Osteoporos Int* 28:775–780

24. Kanis JA, Johansson H, Oden A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdottir K, Fitzpatrick LA, Borgstrom F, McCloskey EV (2018) Characteristics of recurrent fractures. *Osteoporos Int* 29:1747–1757
25. Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. *Arch Osteoporos* 11: 26
26. Giangregorio LM, Leslie WD (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. *J Bone Miner Res* 25:1400–1405
27. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersson C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. *Osteoporos Int* 15:175–179
28. Johnell O, Oden A, Caullin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. *Osteoporos Int* 12:207–214
29. Nymark T, Lauritsen JM, Ovesen O, Rock ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. *Osteoporos Int* 17:1353–1357
30. Roux C, Briot K (2017) Imminent fracture risk. *Osteoporos Int* 28: 1765–1769
31. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. *Ann Rheum Dis* 68:99–102
32. Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, Al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster J-Y (2019) Algorithm for the management of patients at low/middle/high risk of osteoporotic fracture: a global perspective. *Osteoporos Int* 31:1–12
33. Nordström P, Gustafson Y, Michaëlsson K, Nordström A (2015) Length of hospital stay after hip fracture and short term risk of death after discharge: a total cohort study in Sweden. *Bmj* 350:h696
34. Maravic M, Jouaneton B, Vainchtock A, Tochon V (2012) Economic burden of osteoporosis in women: data from the 2008 French hospital database (PMSI). *Clin Exp Rheumatol* 30:222–227
35. Bassgen K, Westphal T, Haar P, Kundt G, Mittlmeier T, Schober HC (2013) Population-based prospective study on the incidence of osteoporosis-associated fractures in a German population of 200, 413 inhabitants. *J Public Health (Oxf)* 35:255–261
36. Carnevale V, Nieddu L, Romagnoli E, Bona E, Piemonte S, Scillitani A, Minisola S (2006) Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. *Osteoporos Int* 17:478–483
37. Caeiro JR, Bartra A, Mesa-Ramos M, Etxebarria I, Montejo J, Carpintero P, Sorio F, Gatell S, Farre A, Canals L (2017) Burden of first osteoporotic hip fracture in Spain: a prospective, 12-month, observational study. *Calcif Tissue Int* 100:29–39
38. National Hip Fracture Database annual report (2017) Falls and Fragility Fracture Audit Programme Royal College of Physicians, London
39. Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: a compendium of country-specific reports. *Arch Osteoporos* 8:137
40. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Mortality after osteoporotic fractures. *Osteoporos Int* 15:38–42
41. Svedbom A, Borgstrom F, Hernlund E, Strom O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lember M, Lesnyak O, McCloskey E, Sanders KM, Silverman S, Solodovnikov A, Tamulaitiene M, Thomas T, Toroptsova N, Uuskula A, Tosteson ANA, Jonsson B, Kanis JA (2018) Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures—results from the ICUROS. *Osteoporos Int* 29: 557–566
42. Szende A, Janssen B, Cabases J (2014) Self-reported population health: an international perspective based on EQ-5D. Springer, Dordrecht (NL)
43. World Health Organization (2018) Metrics: disability-adjusted life year (DALY). http://www.who.int/healthinfo/global_burden_disease/metrics_daly/en/ Accessed 12/10/2017
44. Institute for Health Metrics and Evaluation (IHME) (2016) GBD compare data visualization. <https://vizhub.healthdata.org/gbd-compare/>
45. Borgstrom F, Lekander I, Ivergard M, Strom O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson AN, Jonsson B, Kanis JA (2013) The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)—quality of life during the first 4 months after fracture. *Osteoporos Int* 24:811–823
46. Svedbom A, Borgstrom F, Hernlund E, Strom O, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Uuskula A, Lember M, Kallikorm R, Lesnyak O, McCloskey E, Ershova O, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson ANA, Jonsson B, Kanis JA (2017) Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. *Qual Life Res* 27:707–716
47. Kaffashian S, Raina P, Oremus M, Pickard L, Adachi J, Papadimitropoulos E, Papaioannou A (2011) The burden of osteoporotic fractures beyond acute care: the Canadian Multicentre Osteoporosis Study (CaMos). *Age Ageing* 40:602–607
48. Eurocarers.org (2018) The situation of carers in the EU
49. McKercher HG, Crilly RG, Kloseck M (2000) Osteoporosis management in long-term care. Survey of Ontario physicians. *Can Fam Physician* 46:2228–2235
50. Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jonsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos* 6:59–155
51. Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 30:3–44
52. l'Assurance Maladie (2016) Améliorer la qualité du système de santé et maîtriser les dépenses. Propositions de l'Assurance Maladie pour 2016, 2016 edn
53. Klop C, Gibson-Smith D, Elders PJ, Welsing PM, Leufkens HG, Harvey NC, Bijlsma JW, van Staa TP, de Vries F (2015) Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. *Osteoporos Int* 26:1919–1928
54. Hovstadius B, Astrand B, Petersson G (2009) Dispensed drugs and multiple medications in the Swedish population: an individual-based register study. *BMC Clin Pharmacol* 9:11
55. Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J (2013) SCOPE: a scorecard for osteoporosis in Europe. *Arch Osteoporos* 8:144
56. International Osteoporosis Foundation (2016) Development of the FRAX tool. <https://www.iofbonehealth.org/news/development-frax-tool> Accessed 05/03/2018
57. Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. *Arch Osteoporos* 11:25

58. University of Sheffield (2008) FRAX Fracture Risk Assessment Tool. <https://www.sheffield.ac.uk/FRAX/>
59. Deutschsprachigen Wissenschaftlichen Osteologischen (2014) DVO Leitlinie Osteoporose 2014 Kurzfassung und Langfassung http://www.dv-osteologie.org/dvo_leitlinien/osteoporose-leitlinie-2014 Accessed 03/06/2018
60. Rendl S, Lapa C, Blumel C, Bundschuh RA, Schneider P (2013) Decision making for osteoporotic treatment using FRAX or DVO risk algorithms in a clinical setting. *J Musculoskelet Neuronal Interact* 13:339–345
61. Bonaccorsi G, Fila E, Cervellati C, Romani A, Giganti M, Rossini M, Greco P, Massari L (2015) Assessment of fracture risk in a population of postmenopausal Italian women: a comparison of two different tools. *Calcif Tissue Int* 97:50–57
62. National Institute for Health and Clinical Excellence (2012) Osteoporosis: fragility fracture risk: osteoporosis: assessing the risk of fragility fracture. Royal College of Physicians (UK) National Clinical Guideline Centre., London
63. l'Assurance Maladie (2018) Ostéoporose : diagnostic et évolution. <https://www.ameli.fr/loiret/assure/sante/themes/osteoporose/diagnostic-evolution> Accessed 03/06/2018
64. Tarantino U, Iolascon G, Cianferotti L, Masi L, Marcucci G, Giusti F, Marini F, Parri S, Feola M, Rao C, Piccirilli E, Zanetti EB, Cittadini N, Alvaro R, Moretti A, Calafiore D, Toro G, Gimigliano F, Resmini G, Brandi ML (2017) Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. *J Orthop Traumatol* 18:3–36
65. Ministero della Salute (Italian Ministry of Health) (2011) 1.12. Prevenzione delle fratture da fragilità. <http://www.rssp.salute.gov.it/rssp/paginaParagrafoRssp.jsp?sezione=risposte&capitolo=interventi&id=2745> Accessed 02/27/2018
66. Societa Italiana di Ortopedia e Traumatologia (2017) Le Linee Guida. <http://www.siot.it/pagine/soci/linee-guida.html> Accessed 03/13/2018
67. Ministerio de Sanidad S.Sel., (Spanish Ministry of Health) (2010) Guía de Práctica Clínica sobre Osteoporosis y Prevención de Fracturas por Fragilidad. http://www.guiasalud.es/GPC/GPC_476_Osteoporosis_AIAQS_compl.pdf Accessed 02/27/2018
68. Socialstyrelsen (The Swedish Welfare Agency) (2018) Nationella riktlinjer för rörelseorganens sjukdomar – stöd för styrning och ledning. <http://www.socialstyrelsen.se/publikationer2012/2012-5-1> Accessed 02/27/2017
69. The National Institute for Health and Care Excellence (NICE) (2018) Osteoporosis: assessing the risk of fragility fracture. <https://www.nice.org.uk/guidance/cg146/chapter/1-guidance> Accessed 02/27/2018
70. Mitchell PJ (2011) Fracture liaison services: the UK experience. *Osteoporos Int* 22(Suppl 3):487–494
71. Eekman DA, van Helden SH, Huisman AM, Verhaar HJ, Bultink IE, Geusens PP, Lips P, Lems WF (2014) Optimizing fracture prevention: the fracture liaison service, an observational study. *Osteoporos Int* 25:701–709
72. Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B, Eisman JA, Geusens PP, Brink PR (2014) Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. *J Bone Joint Surg Am* 96:e29
73. International Osteoporosis Foundation (2018) Capture the fracture. <http://www.capture-the-fracture.org/>
74. McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. *Osteoporos Int* 22:2083–2098
75. Nakayama A, Major G, Holliday E, Attia J, Bogduk N (2016) Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. *Osteoporos Int* 27:873–879
76. Schray D, Neuerburg C, Stein J, Gosch M, Schieker M, Bocker W, Kammerlander C (2016) Value of a coordinated management of osteoporosis via fracture liaison service for the treatment of orthogeriatric patients. *Eur J Trauma Emerg Surg* 42:559–564
77. Walters S, Khan T, Ong T, Sahota O (2017) Fracture liaison services: improving outcomes for patients with osteoporosis. *Clin Interv Aging* 12:117–127
78. Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. *Bone* 111:92–100
79. Jonsson E, Borgström F, Ström O (2016) PHS49—cost effectiveness evaluation of fracture liaison services for the management of osteoporosis in Sweden. *Value Health* 19:A612
80. Leal J, Gray AM, Hawley S, Prieto-Alhambra D, Delmestri A, Arden NK, Cooper C, Javaid MK, Judge A (2017) Cost-effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: a population-based study. *J Bone Miner Res* 32:203–211
81. Javaid MK, Vasilakis N, Dickinson R, Wiles B, Shah A, Pinedo-Villanueva R (2018) Fracture Liaison Service Database Annual report December 2018. In (FFFAP) RCoPFaFFAP (ed) Fracture Liaison Service Database Annual report, London
82. Leal J, Gray A, Prieto-Alhambra D, Arden NK, Cooper C, Javaid M, Judge A, the REFReSH Study Group (2016) Impact of hip fracture on hospital care costs: a population-based study. *Osteoporos Int* 27:549–558

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.